These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1967036)

  • 1. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
    Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
    J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer cells: culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors.
    Beckner SK; Maluish AE; Longo DL
    Cancer Res; 1987 Oct; 47(20):5504-8. PubMed ID: 3498534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.
    Favrot MC; Coze C; Combaret V; Gaspard M; Colin C; Franks C; Negrier S; Philip I; Philip T
    Mol Biother; 1990 Mar; 2(1):32-7. PubMed ID: 2185792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
    Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
    No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induction of LAK cells by high density dialyzing culture device and its cytotoxicity].
    Kohgo Y; Kanisawa Y; Sakamaki S; Nojiri S; Ueno Y; Ito Y; Niitsu Y; Hosoi S; Sato S; Urushizaki I
    Hum Cell; 1988 Mar; 1(1):54-9. PubMed ID: 3154014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High yielding culture of LAK cells by the concentration rotary tissue culture system and its clinical application].
    Park KC; Shimizu K; Tamura K; Yamada M; Matsui Y; Mabuchi E; Moriuchi S; Mogami H
    Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2349-54. PubMed ID: 2614173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
    Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
    Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
    Ochoa AC; Gromo G; Alter BJ; Sondel PM; Bach FH
    J Immunol; 1987 Apr; 138(8):2728-33. PubMed ID: 2435804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA; Oldham RK; Yannelli JR
    Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
    Koberda J; Przepiorka D; Moser RP; Grimm EE
    Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity in lectin-binding characteristics of human lymphokine-activated killer cells.
    Maruyama T; Imai Y; Harada K; Okada T; Takano M; Ikeda Y; Toda G; Oka H; Osawa T
    J Biol Response Mod; 1990 Aug; 9(4):378-86. PubMed ID: 2395003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ; Silver HK; Kong S
    Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.